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Objective
To define the characteristics of MAS complicating JSLE.
Methods
Patients with JSLE and MAS were collected from: 1)
Gaslini Institute of Genoa, Italy; 2) PRINTO and PRCSG
investigators; 3) literature. Control groups of JSLE without
MAS included 33 patients with active lupus seen at Gaslini
Institute (SLE-GI) and 387 patients from a multinational
study of damage in JSLE (SLE-MS). Clinical and labora-
tory features of MAS with (BM+) or without (BM-) bone
marrow demonstration of haemophagocytosis were con-
trasted each other and with those of lupus without MAS.
Results
20 BM+ and 18 BM-patients with JSLE-associated MAS
were identified. Comparison of percentage frequency of
the main clinical and laboratory features of MAS in
patient groups is shown in table 1.
Conclusion
Features of MAS in patients with or without BM haemo-
phagocytosis were comparable, except for a greater fre-
quency of leukopenia in BM+ patients. This suggests that
this complication is more common than previously real-
ized. All features but leukopenia and fever discriminated
well between MAS and active lupus without MAS.
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Table 1: Comparison of percentage frequency of the main 
clinical and laboratory features of MAS in partient groups. (NA: 
not available)
MAS BM+ MAS BM- SLE-GI SLE-MS
Fever 95.0 83.3 21.2 64.2
Hepatomegaly 47.4 55.6 12.1 10.4
CNS dysfunction 37.5 28.6 3.0 8.5
Haemorrhages 40.0 33.3 9.1 NA
Leukopenia 90.0 44.4 63.6 NA
Thrombocytopenia 90.0 61.1 18.2 NA
Hypertransaminasemia 80.0 93.8 30.3 NA
Hypertriglyceridemia 75.0 88.2 20.0 NA
Hypofibrinogenemia 37.5 42.9 0 NA
Hyperferiitinemia 92.9 94.4 0 NA